RxDoctor Payments Data

Steven Alderfer, NP

Family · Arrington, VANPI 1952389645

Payments from drug & device makers

$936in general payments, 2019–2025

Across 51 payments — averaging $18.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$218
  • Abbott$195
  • Lilly USA, LLC$120
  • AbbVie$75
  • Pfizer$69
  • AstraZeneca$66
  • plus $194 from 8 others

What the payments were for

  • Food & beverage$90497%
  • Education$313%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$936 in reported general payments places this provider in the 70th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$3,436
Medicare patients
121
Services billed
240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide100$133,264
TrulicityDulaglutide80$117,264
JardianceEmpagliflozin80$109,511
EliquisApixaban61$79,176
Tresiba Flextouch U-200Insulin Degludec56$71,055
JanuviaSitagliptin Phosphate51$70,246
FarxigaDapagliflozin Propanediol35$31,174
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$22,029
OzempicSemaglutide11$18,840
MyrbetriqMirabegron14$10,869
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$10,829
Dexlansoprazole DrDexlansoprazole33$10,451
Tresiba Flextouch U-100Insulin Degludec11$8,887
SymbicortBudesonide/Formoterol Fumarate22$8,537
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate28$8,273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$120$250,528180 claims
PfizerEliquis$69$79,17661 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$66$61,74074 claims
Novo NordiskOzempic$52$18,84011 claims
Astellas Pharma US IncMyrbetriq$33$10,86914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,332 family providers in Virginia.

Other family in Arrington

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →